{"title":"Oral Fosfomycin for Pyelonephritis: Re-examining the Pooled Evidence.","authors":"Recep Balik","doi":"10.1093/cid/ciag710","DOIUrl":"https://doi.org/10.1093/cid/ciag710","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2026-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Lionel Martellet, Dhananjay Kapse, Prasad S Kulkarni, Ed Clarke, Magnus Ochoge, Ama Umesi, Milagritos Tapia, Samba Sow, Fadima Haidara, Fatoumata Diallo, Yuxiao Tang, Mark R Alderson, Niranjan Bhat, Jo Anne Welsch, Nancy Hosken, F Marc LaForce
{"title":"Immune persistence up to one year after a single dose of pentavalent meningococcal ACYWX conjugate vaccine (NmCV-5) administered to children, adolescents and adults (2-29 years of age) in Mali and The Gambia.","authors":"Lionel Martellet, Dhananjay Kapse, Prasad S Kulkarni, Ed Clarke, Magnus Ochoge, Ama Umesi, Milagritos Tapia, Samba Sow, Fadima Haidara, Fatoumata Diallo, Yuxiao Tang, Mark R Alderson, Niranjan Bhat, Jo Anne Welsch, Nancy Hosken, F Marc LaForce","doi":"10.1093/cid/ciag693","DOIUrl":"https://doi.org/10.1093/cid/ciag693","url":null,"abstract":"<p><p>A meningococcal ACYWX conjugate vaccine (NmCV-5) has been developed to address epidemic meningitis in Sub-Saharan Africa. During a phase 3 observer-blind clinical trial in 2- to 29-year-olds in Mali and The Gambia, a single dose of either NmCV-5 or a licensed quadrivalent ACYW conjugate vaccine (MenACYW-D) was found to be safe and immunogenic 28 days post-vaccination. Among the original 1800 study participants, a subset of 786 was further evaluated for immune responses by rabbit complement serum bactericidal assay (rSBA) at 6 and 12 months after immunization. At 12 months post-immunization, 100% of NmCV-5 group retained titers ≥128 for serogroups A, Y, and W, 99.8% for X and 90.9% for serogroup C. For the MenACYW-D group, 100% retained titers ≥128 for A, 99.6% for Y, 98.1% for W, 74.8% for serogroup C, and 89.9% for X. The seroresponse rate in the NmCV-5 group was 58% for A, 91.5% for Y, 96.4% for W, 82.6% for X and 89.8% for C. In the MenACYW-D group, the seroresponse rate was 37.6% for A, 86.1% for Y, 92.7% for W, 75.5% for C, and 7.1% for X. Geometric mean titers (GMTs) declined between 28 days and 12 months. At 12 months, in the NmCV-5 group they were at 985 for C and >4096 for all other serogroups. In the MenACYW-D group, GMTs were 269 for C, >2048 for A, W, Y and remained at baseline levels for X. Further investigation is needed at later timepoints to project NmCV-5 duration of protection.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Matthew R Golden, Chase A Cannon, Timothy W Menza, Monisha Sharma, Kathryn M Porter, Julia C Dombrowski
{"title":"Integrating Cost Considerations into HIV Care and Prevention to Achieve Population-Level Outcomes.","authors":"Matthew R Golden, Chase A Cannon, Timothy W Menza, Monisha Sharma, Kathryn M Porter, Julia C Dombrowski","doi":"10.1093/cid/ciag713","DOIUrl":"https://doi.org/10.1093/cid/ciag713","url":null,"abstract":"<p><p>The US government currently spends >$29 billion annually on HIV treatment, but only 69% of people with diagnosed HIV (PWH) in the US are virally suppressed, a failure partially related to poverty. Medical providers preferentially treat HIV using higher cost medications, and use of higher cost drugs for PrEP is increasing. New, long-acting antiretrovirals (ARVs) have the potential to improve prevention and care while further increasing costs. We believe that the US approach to HIV should change to increase the use of lower cost HIV medications and promote the selective use of long-acting ARVs to treat people who cannot achieve viral suppression using oral drugs. A portion of the money saved through more efficient medication utilization management should be used to improve access to care and provide socioeconomic support to low-income PWH. Together, these changes have the potential to decrease costs, improve health outcomes, and better align spending with patient preferences.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"House of Cards: Changing HIV Medication Utilization and Pricing Patterns Will Require a Funding Balancing Act.","authors":"Amy Killelea, Kathleen A McManus","doi":"10.1093/cid/ciag714","DOIUrl":"https://doi.org/10.1093/cid/ciag714","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2026-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Weiming Zhu, Rupa R Patel, Ya-Lin A Huang, Nicole L Davis, Karen W Hoover, Athena P Kourtis
{"title":"CAB-LA PrEP Prescriptions and Abandonment in the United States, January 2022-June 2025.","authors":"Weiming Zhu, Rupa R Patel, Ya-Lin A Huang, Nicole L Davis, Karen W Hoover, Athena P Kourtis","doi":"10.1093/cid/ciag721","DOIUrl":"https://doi.org/10.1093/cid/ciag721","url":null,"abstract":"<p><strong>Background: </strong>Injectable long-acting cabotegravir (CAB-LA) for HIV preexposure prophylaxis (PrEP) was approved by the US Food and Drug Administration in 2021. A national assessment of CAB-LA PrEP abandonment, defined as not filling any prescription, could inform national PrEP implementation efforts.</p><p><strong>Methods: </strong>We conducted a national observational cohort study using IQVIA Longitudinal Prescription data to characterize persons prescribed CAB-LA or daily oral PrEP (DO-PrEP) in the United States during January 2022-June 2025. We compared 6-month abandonment risk among individuals with an index CAB-LA or DO-PrEP prescription during 2022-2024. Associations were estimated using multivariable modified Poisson regression models and reported as adjusted risk ratios (aRRs) with 95% confidence intervals (CIs).</p><p><strong>Results: </strong>The number of individuals prescribed CAB-LA PrEP increased from 4,645 in 2022 to 23,378 in 2024 and 25,018 during January-June 2025. The proportion of individuals receiving CAB-LA increased from 0.1% in quarter 1 of 2022 to 5.4% in quarter 2 of 2025. While women had a higher 6-month PrEP abandonment risk than men, regardless of PrEP regimen, they were less likely to abandon CAB-LA (11.9%) than DO-PrEP (18.1%, aRR=0.68, 95% CI: 0.62-0.74). The opposite was observed for men, with men more likely to abandon CAB-LA PrEP (10.2%) than DO-PrEP (8.1%, aRR=1.25, 95% CI: 1.20-1.31).</p><p><strong>Conclusions: </strong>CAB-LA PrEP prescribing increased steadily during the first 3.5 years after approval; abandonment risk differed by PrEP regimen and sex. Addressing barriers to injectable and daily oral PrEP uptake, and strengthening sex-specific PrEP implementation strategies, may further reduce abandonment risk.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Practice Structures and Compensation for Transplant Infectious Diseases: A First Step to Charting the Future of the Field.","authors":"Joanna Schaenman, Michael G Ison","doi":"10.1093/cid/ciag716","DOIUrl":"https://doi.org/10.1093/cid/ciag716","url":null,"abstract":"","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emily M Eichenberger, Andrea J Zimmer, Steven A Pergam, Pearlie Chong, Aruna Subramanian, Paul Sue, Maricar Malinis
{"title":"Transplant Infectious Disease Physician Workforce: A National Survey of Practice Structure, Compensation, and Job Satisfaction.","authors":"Emily M Eichenberger, Andrea J Zimmer, Steven A Pergam, Pearlie Chong, Aruna Subramanian, Paul Sue, Maricar Malinis","doi":"10.1093/cid/ciag715","DOIUrl":"https://doi.org/10.1093/cid/ciag715","url":null,"abstract":"<p><strong>Background: </strong>Transplant Infectious Diseases (TID) is a growing, clinically complex subspecialty essential to transplant and oncology programs, yet the practice structure, compensation, and professional experience of TID physicians in the United States remain poorly characterized.</p><p><strong>Methods: </strong>The IDSA Immunocompromised Host Community of Practice Leadership Group conducted a cross-sectional survey of U.S.- based TID physicians.</p><p><strong>Results: </strong>A total of 184 physicians responded to the survey (86% adult, 13% pediatric; 94% academic). Adult TID physicians worked a median of 17 weeks (IQR 12-24) plus 8 (IQR 6-12)weekends per year on inpatient service, along with 1.5 half day clinics (IQR 1-2) outpatient. Physicians reported that a median of 67% of their non-clinical duties were not supported with FTE. Median base salary for adult TID physicians in an academic setting was $235,000 (IQR $205,000-$274,000), and $205,000 (IQR $183,000-$235,000) for pediatrics. Only 5% of junior faculty felt comfortable negotiating compensation. Forty-nine percent of respondents felt undercompensated, though 78.7% were satisfied or very satisfied with their job.</p><p><strong>Conclusions: </strong>This first national characterization of the TID workforce reveals substantial compensation inequity and unfunded non-clinical work alongside high job satisfaction and strong collegial value. Policy mandates, FTE protections, compensation transparency, and negotiation training are needed to sustain this workforce.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149393187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ping Yang, Xianming Zhu, Eshan U Patel, Thomas C Quinn, Matthew M Hamill, Aaron A R Tobian, Mary K Grabowski
{"title":"National Trends in Congenital Syphilis Among US Newborns, 2012-2022.","authors":"Ping Yang, Xianming Zhu, Eshan U Patel, Thomas C Quinn, Matthew M Hamill, Aaron A R Tobian, Mary K Grabowski","doi":"10.1093/cid/ciag588","DOIUrl":"https://doi.org/10.1093/cid/ciag588","url":null,"abstract":"<p><p>Congenital syphilis among US birth hospitalizations increased 5.9-fold (95% CI = 4.9-7.2) from 2012 to 2022 in the Kids' Inpatient Database. Increases were observed across all demographics, income levels, and hospital settings, with the largest increase among Native Americans (21.5-fold; 95% CI = 8.8-52.1). These findings underscore the need for improved syphilis prevention and prenatal screening efforts.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicolas de Prost, Pierre Bay, Marie Le Goff, Sébastien Préau, Aurélie Guigon, François M Beloncle, Caroline Lefeuvre, Anaïs Dartevel, Sylvie Larrat, Rémi Coudroy, Luc Deroche, Cédric Darreau, Jean Thomin, Cécile Aubron, Adissa Tran, Fabrice Uhel, Quentin Le Hingrat, Fabienne Tamion, Alice Moisan, Antoine Guillon, Lynda Handala, Bertrand Souweine, Cecile Henquell, Kada Klouche, Edouard Tuaillon, Charles Damoisel, Anne-Marie Roque-Afonso, Elyanne Gault, Pierre Cappy, Alexandre Soulier, Jean-Michel Pawlotsky, Frédéric Lemoine, Marie-Anne Rameix-Welti, Etienne Audureau, Slim Fourati
{"title":"People With Influenza Requiring ICU Admission During the 2025-2026 Season, Marked by the Emergence of Influenza A(H3N2) Subclade K: A French Prospective Nationwide Cohort Study.","authors":"Nicolas de Prost, Pierre Bay, Marie Le Goff, Sébastien Préau, Aurélie Guigon, François M Beloncle, Caroline Lefeuvre, Anaïs Dartevel, Sylvie Larrat, Rémi Coudroy, Luc Deroche, Cédric Darreau, Jean Thomin, Cécile Aubron, Adissa Tran, Fabrice Uhel, Quentin Le Hingrat, Fabienne Tamion, Alice Moisan, Antoine Guillon, Lynda Handala, Bertrand Souweine, Cecile Henquell, Kada Klouche, Edouard Tuaillon, Charles Damoisel, Anne-Marie Roque-Afonso, Elyanne Gault, Pierre Cappy, Alexandre Soulier, Jean-Michel Pawlotsky, Frédéric Lemoine, Marie-Anne Rameix-Welti, Etienne Audureau, Slim Fourati","doi":"10.1093/cid/ciag648","DOIUrl":"https://doi.org/10.1093/cid/ciag648","url":null,"abstract":"<p><strong>Background: </strong>Intense influenza activity has been reported alongside the emergence of influenza A(H3N2) subclade K. While epidemiological studies have reported heterogeneous findings regarding public health impact, data remain lacking on its impact on clinical phenotype of people requiring intensive care unit (ICU) admission.</p><p><strong>Methods: </strong>Prospective, multicenter, observational SEVARVIR cohort study including people admitted in 42 French ICUs with laboratory-confirmed influenza infection during the 2024-2025 and 2025-2026 seasons. Primary end point was day-28 mortality.</p><p><strong>Results: </strong>Seven hundred twenty-six people were admitted for influenza in 2024-2025 (n = 360) and 2025-2026 (n = 366). In 2025-2026, influenza subtype was available for 265 people; 49% (n = 129) had A(H1N1)pdm09 and 51% (n = 136) had A(H3N2) subtype infection. Among the 40 people with A(H3N2) infection for whom whole-genome sequencing was available, 33 (82.5%) belonged to subclade K. In multivariable Cox analysis of the 2025-2026 season, age (adjusted hazard ratio, aHR = 1.04 [1.01;1.09]; P = .015), Clinical Frailty Scale (aHR = 1.59 [1.28;1.98]; P < .001), and sequential organ failure assessment score (aHR = 1.15 [1.05;1.26]; P = .003) were associated with an increased risk of death. In the 2024-2025/2025-2026 seasons or 2025-2026 season alone, influenza subtype was not associated with a significant risk of day-28 mortality. Phylogenetic analyses from our ICU cohort together with 600 contextual sequences from community-acquired influenza cases collected during the period showed no clustering according to severity.</p><p><strong>Conclusions: </strong>There was no evidence of an increased risk of death among critically ill people with influenza during the 2025-2026 season, despite the emergence of influenza A(H3N2) subclade K.</p><p><strong>Trial registration: </strong>NCT05162508.</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.3,"publicationDate":"2026-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}